Literature DB >> 22723562

Neither subendplate cement deposition nor cement leakage into the disk space during vertebroplasty significantly affects patient outcomes.

Ankaj Khosla1, Felix E Diehn, Arash Ehteshami Rad, David F Kallmes.   

Abstract

PURPOSE: To determine the impact of cement placement immediately adjacent to and through the endplate during percutaneous vertebroplasty on postprocedural pain and subsequent fracture rate.
MATERIALS AND METHODS: Institutional review board approval with waived consent was obtained. Medical records of 424 patients undergoing first-time, single-level vertebroplasty for osteoporotic or traumatic compression fractures were examined. Data regarding pain at rest and with activity before the procedure, along with timing and level of subsequent fractures over a 24-month period, were collected. Group 1 (n=64) included patients with no cement extension to the endplate(s), group 2 (n=216) included those with cement extension to the endplate(s) but no leakage into the disk space(s), and group 3 (n=144) included those with cement extension to the endplate(s) and cement leakage into the disk space(s). Analysis of variance and Fisher test were used to analyze the data, with significance set at P<.05.
RESULTS: Baseline characteristics and demographics were similar among the groups. At 1 month, for groups 1, 2, and 3, the respective mean postprocedural pain numeric scores at rest were 1.4±2.7, 1.4±2.4, and 1.6±2.5 (P=.51), while the respective pain scores with activity were 4.3±2.9, 3.8±3.1, and 3.9±3.3 (P=.50). Total subsequent fractures were noted in five (8%), 26 (12%), and 15 (10%) patients in group 1, 2, and 3, respectively (P=.77).
CONCLUSION: Neither extension of cement to the endplate nor cement leakage into the disk space has significant impact on postprocedural pain or subsequent fracture rate at 2 years. © RSNA, 2012.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22723562     DOI: 10.1148/radiol.12112215

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  7 in total

1.  Evaluation of pain reduction and height restoration post vertebral augmentation using a polyether ether ketone (PEEK) polymer implant for the treatment of split (Magerl A2) vertebral fractures: a prospective, long-term, non-randomized study.

Authors:  Georgios Velonakis; Dimitrios Filippiadis; Stavros Spiliopoulos; Elias Brountzos; Nikolaos Kelekis; Alexis Kelekis
Journal:  Eur Radiol       Date:  2018-12-03       Impact factor: 5.315

2.  Analysis of risk factors of subsequent fractures after vertebroplasty.

Authors:  Gang Sun; Hai Tang; Min Li; Xunwei Liu; Peng Jin; Li Li
Journal:  Eur Spine J       Date:  2013-11-20       Impact factor: 3.134

3.  [Cement augmentation for osteoporotic compression fractures].

Authors:  M J Lee; J G Jarvik
Journal:  Unfallchirurg       Date:  2012-12       Impact factor: 1.000

4.  Is severe pain immediately after spinal augmentation a predictor of long-term outcomes?

Authors:  Y W Cho; J S McDonald; A E Rad; J J Ocel; D F Kallmes
Journal:  AJNR Am J Neuroradiol       Date:  2013-04-18       Impact factor: 3.825

5.  Complications of percutaneous vertebroplasty: An analysis of 1100 procedures performed in 616 patients.

Authors:  Agnieszka Saracen; Zbigniew Kotwica
Journal:  Medicine (Baltimore)       Date:  2016-06       Impact factor: 1.889

6.  Efficacy and safety of high-viscosity cement in percutaneous vertebroplasty for treatment of Osteoporotic vertebral compression fractures: A retrospective cohort study.

Authors:  Kunpeng Li; Hongyong Feng; Dawei Luo; Wen Zhang; Keshi Yang; Changbin Ji; Jinlong Liu; Hui Xu
Journal:  Medicine (Baltimore)       Date:  2020-06-05       Impact factor: 1.817

7.  Risk factors of neurological deficit and pulmonary cement embolism after percutaneous vertebroplasty.

Authors:  Ming-Kai Hsieh; Fu-Cheng Kao; Ping-Yeh Chiu; Lih-Huei Chen; Chia-Wei Yu; Chi-Chien Niu; Po-Liang Lai; Tsung-Ting Tsai
Journal:  J Orthop Surg Res       Date:  2019-11-29       Impact factor: 2.359

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.